Symbollon Pharmaceuticals Inc. has announced the formation of its first Commercialization Advisory Board to spearhead the launch and ongoing sales and distribution of its proprietary and patented molecular iodine product, Iogen(TM) specifically formulated as a dietary supplement for improved women's breast health. The Board members have played an integral role in the development of the newly designed retail website and in the commercial launch of Iogen(TM) to the public which is anticipated to begin March 4, 2010. The board is made up of a team of commercialization experts who, when combined, have many decades of experience in the retail sales, distribution, marketing and advertising industries. Roger Wist and Mike Griak, of Wist-Griak & Associates have over 60 years of combined sales, marketing and advertising experience. Roger has been integral to several start-ups and has a vertical understanding of all marketing components and package design and how to balance them to be both impactful and cost effective. Mike has an extensive background in the advertising world having launched and managed multiple brands for companies such as Schwan's, Pillsbury and Hormel Foods. David Ghiz led the retail growth and expansion of Paddock Pool Construction Company from 1985 until the family sold the business in 2005. This newly formed Commercialization Advisory Board will assist Symbollon with all aspects of positioning the company as the premier women's health and wellness biotechnical company in the world. It will include the marketing and selling of Iogen(TM) and other brands and products under development by the company, including the personal lubricant product Sylk(TM), which the company announced it is in the process of acquiring.

Symbollon Pharmaceuticals Inc. has decided to internalize the retail launch of IoGen(TM), its dietary supplement for women's breast health. IoGen is the first dietary supplement formulated to promote breast health for women. The company plans to market IoGen through various retail channels, including sales through its own internet web site.

On June 30, 2009, Symbollon Pharmaceuticals Inc. signed a distribution agreement with Integra Labs Inc. granting Integra the exclusive right to distribute Symbollon's dietary supplement, IoGen-TM-, in countries allowing over-the-counter sales of the product. Under the agreement, Integra will assume all manufacturing, sales and marketing responsibilities for the product. Integra will purchase Symbollon's existing inventory of IoGen at cost. Integra shall pay Symbollon a royalty on all sales of IoGen. The initial term of the agreement is for five years, subject to the achievement of certain milestones and minimum sales requirements. Pursuant to the agreement, the parties intend to identify other OTC product opportunities for Symbollon's iodine technology which would be distributed by Integra.

iogen to Be Presented at Natural Products Expo West

iogen to Be Presented at Natural Products Expo West

Symbollon Hits Its First Major Milestone

Symbollon Hits Its First Major Milestone

Symbollon Establishes Commercialization Advisory Board

Symbollon Establishes Commercialization Advisory Board

The Sylk(R) Health and Personal Care Product Line to Be Acquired by Symbollon

The Sylk(R) Health and Personal Care Product Line to Be Acquired by Symbollon

Women's Breast Health Supplement to Be Launched by Symbollon

Symbollon Pharmaceuticals Announces Agreement With Integra Labs, Inc. for Distribution of IoGen(TM)

Woman's Breast Health Supplement, IoGen(TM), Available to Public in February From Symbollon Pharmaceuticals

Symbollon Retains Atech Solutions to Enhance Web Presence and Build Retail Site for the Sales of IoGen

Woman's Breast Health Supplement, IoGen(TM), Available to Public in February From Symbollon Pharmaceuticals

Symbollon Retains Atech Solutions to Enhance Web Presence and Build Retail Site for the Sales of IoGen

Women's Breast Health Supplement to Be Launched by Symbollon

SYMBOLLON CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhibits

Symbollon Enters Into Sale/License Agreement Covering Upper Respiratory Tract Technology

SYMBOLLON CORP Files SEC form 10-Q, Quarterly Report

SYMBOLLON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities

Symbollon Pharmaceuticals Announces 2008 Year-End Results